Further clinical studies are ongoing to test adoptive cytotoxic T cells that target preferentially expressed antigen in melanoma (PRAME), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), MAGE Family member A4 (MAGEA4), synovial sarcoma translocated gene (SSX), and survivin in patients with advanced tumors, including TCs. The gene discussed is MAGEA4; the disease is esophageal squamous cell carcinoma.